Levodopa in Parkinson's disease: from the past to the future

Bibliography

• De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6
   PubMed Web of Science ®Google Scholar
• Thanvi BR, Munshi SK, Vijaykumar N, Lo T. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J 2003;79:561-5
   PubMed Web of Science ®Google Scholar
• Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Martin W, Suchowersky O, Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58(1):11-7
   PubMedGoogle Scholar
• Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 [review]. Mov Disord 2005;20(5):523-39
   PubMed Web of Science ®Google Scholar
• Horstink M, Tolosa E, Bonuccelli U, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease [review]. Eur J Neurol 2006;13(11):1186-202
   PubMed Web of Science ®Google Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-9
   PubMed Web of Science ®Google Scholar
• Koller WC. Levodopa in the treatment of Parkinson's disease. Neurology 2000; 55(11 Suppl 4):S2-7
   PubMedGoogle Scholar
• Jankovic J. Levodopa strengths and weaknesses. Neurology 2002;58(4 Suppl 1):S19-32
   Google Scholar
• Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10:331-9
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang SM, Schwarzschild MA, Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord 2006;21:1002-7
   PubMedGoogle Scholar
• Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23(10 Suppl):S2-7
   PubMed Web of Science ®Google Scholar
• Lang AP, Lozano AE. Parkinson's disease. N Engl J Med 1998;339:1044-53
   PubMed Web of Science ®Google Scholar
• Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther 2005;47:12
   PubMedGoogle Scholar
• Stocchi F, Fabbri L, Vecsei L, Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007;30:18-24
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23
   PubMed Web of Science ®Google Scholar
• Holtz P. Dopadecarboxylase. Naturwissenschaften 1993;27:724-5
   Google Scholar
• Godwin-Austen RB. The long term therapeutic effect of levodopa in the treatment of Parkinsonism. Adv Neurol 1973;3:23-7
   Google Scholar
• Wade DN, Mearrick PT, Morris JL. Active transport of L-DOPA in the intestine. Nature 1973;242:463-5
   PubMed Web of Science ®Google Scholar
• Hardie RJ, Malcolm SL, Lees AJ, The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 1986;22:429-36
   PubMed Web of Science ®Google Scholar
• Nutt JG, Feldman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, The “on-off” phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984b;310:483-488
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Anderson JL. Effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of Parkinsonism. Ann Neurol 1985;18:537-44
   PubMed Web of Science ®Google Scholar
• Wade LA, Katzman R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975;17:131-6
   PubMedGoogle Scholar
• Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther 1981;217:189-97
   PubMedGoogle Scholar
• Poewe W. L-dopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins, 1993:103-113
   Google Scholar
• Schwartz J-C, Giros B, Martres M-P, The dopamine receptor family: molecular biology and pharmacology. Semin Neurosci 1992;4:99-108
   Google Scholar
• Obeso JA, Luquin MR, Grandas F, Motor response to repeated dopaminergic stimulation in Parkinson's disease. Clin Neuropharmacol 1992;15:75-9
   PubMedGoogle Scholar
• Oreland L. Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol Scand Suppl 1991;136(Suppl 136):60-65
   PubMedGoogle Scholar
• Callier S, Snapyan M, Le Crom S, Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell 2003;95:489-502
   PubMed Web of Science ®Google Scholar
• Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004;61:641-4
   PubMed Web of Science ®Google Scholar
• Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-73
   PubMed Web of Science ®Google Scholar
• Sossi V, Fuente-Fernandez R, Holden JE, Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004;24:869-76
   PubMed Web of Science ®Google Scholar
• Tedroff J, Pedersen M, Aquilonius S-M, Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 1996;46:1430-6
   PubMed Web of Science ®Google Scholar
• Witjas T, Kaphan E, Azulay JP, Non motor fluctuations in Parkinson's disease: frequent and disabiling. Neurology 2002;59:408-13
   PubMed Web of Science ®Google Scholar
• Mayeux R, Chen J, Mirabello E, An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;40:1513-7
   PubMed Web of Science ®Google Scholar
• Brown RG, MacCarthy B, Gotham AM, Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med 1988;18:49-55
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson's disease and dementia with Lewy body. Neurology 2004;63:1093-5
   PubMed Web of Science ®Google Scholar
• Arnulf I, Konofal E, Merino-Andreu M, Parkinson's disease and sleepniess: an integral part of PD. Neurology 2002;58:1019-24
   PubMed Web of Science ®Google Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123(pt 11):2297-305
   PubMedGoogle Scholar
• Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55(11 Suppl 4):S72-7; discussion S78-81
   PubMed Web of Science ®Google Scholar
• Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23(10 Suppl):S109-115
   Google Scholar
• Metman LV, Del Dotto P, LePoole K, Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-6
   PubMed Web of Science ®Google Scholar
• Jenner P, Mori A, Hauser R, Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009;15:40613
   Google Scholar
• Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009;8:67-81
   PubMed Web of Science ®Google Scholar
• Bravi D, Mouradian MM, Roberts JW, Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508
   PubMed Web of Science ®Google Scholar
• Stocchi F. Optimising levodopa therapy for the management of Parkinson's disease. J Neurol 2005;252(Suppl 4):IV43-8
   PubMedGoogle Scholar
• Goole J, Deleuze P, Vanderbist F, Amighi K. New levodopa substained-relase floating minitablets coated with insoluble acrylic polymer. Eur J Pharm. Biopharm 2008;68:310-8
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rubin AJ, Miller C, Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-5
   PubMed Web of Science ®Google Scholar
• Sage JI, Trooskin S, Sonsalla PK, Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-9
   PubMed Web of Science ®Google Scholar
• Ruggieri S, Stocchi F, Carta A, Jejunal delivery of levodopa methylester. Lancet 1989;8653:45-6
   Google Scholar
• Syed N, Murphy J, Zimmerman T, Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-8
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
   PubMed Web of Science ®Google Scholar
• Babita K, Tiwary AK. Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa. Curr Drug Deliv 2004;1:397-403
   PubMedGoogle Scholar
• Iwase H, Sudo J, Terui J, Transdermal absorption of L-dopa from a new system composed of two separate layers of L-dopa and hydrogel in rats. Drug Dev Ind Pharm 2000;26:755-9
   PubMed Web of Science ®Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18
   PubMed Web of Science ®Google Scholar
• Kao HD, Traboulsi A, Ithoh S, Enhancement of the systemic and CNS specific delivery of L-DOPA by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17:978-84
   PubMed Web of Science ®Google Scholar
• Bartus RT, Emerich D, Snodgrass-Belt P, Pulmonary formulation of L-dopa enhance its effectiveness in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:828-35
   PubMed Web of Science ®Google Scholar
• Björklund A, Dunnett SB, Brundin P, Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003;2(7):437-45
   PubMedGoogle Scholar
• Kordower JH, Freeman TB, Snow BJ, Neuropathologic evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Eng J Med 1995;332:1118-24
   PubMed Web of Science ®Google Scholar
• Freed CR, Greene PE, Breeze RE, Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New Eng J Med 2001;344:710-9
   PubMed Web of Science ®Google Scholar
• Takagi Y, Takahashi J, Saiki H, Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 2005;115:102-9
   PubMed Web of Science ®Google Scholar
• Olanow CW. Can we achieve neuroprotection with currently available antiparkinsonian interventions? Neurology 2009;72(7 Suppl):S59-64
   Google Scholar
• Fazzini E, Dwork AJ, Blum C, Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism. One-year follow-up. Arch Neurol 1991;48(8):813-20
   PubMedGoogle Scholar
• Ren Z, Zhang Y. Cell therapy for Parkinson's disease–so close and so far away. Sci China C Life Sci 2009;52:610-4
   PubMedGoogle Scholar